ACP: Next-Generation Antibiotics Underused for Gram-Negative Infections
By Elana Gotkine HealthDay Reporter
MONDAY, April 22, 2024 -- Clinicians frequently treat gram-negative infection with older, generic antibiotics, despite recent approval of next-generation, gram-negative antibiotics, according to a study published online April 19 in the Annals of Internal Medicine to coincide with the Internal Medicine Meeting, the annual meeting of the American College of Physicians, held from April 18 to 20 in Boston.
In a retrospective cohort study at 619 U.S. hospitals, Jeffrey R. Strich, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues examined use patterns of recently U.S. Food and Drug Administration-approved gram-negative antibiotics and identified factors associated with their preferential use over traditional generic agents in patients with gram-negative infections due to pathogens displaying difficult-to-treat resistance (DTR).
The researchers found that ceftolozane-tazobactam (approved in 2014) and ceftazidime-avibactam (approved in 2015) predominated new antibiotic usage between quarter 1 of 2016 and quarter 2 of 2021, while there was relatively low uptake of subsequently approved gram-negative antibiotics. Overall, 0.7 percent of the gram-negative infection hospitalizations displayed DTR pathogens. In 41.5 percent of DTR episodes, patients were treated exclusively using traditional agents, including reserve antibiotics such as polymyxins, aminoglycosides, and tigecycline in 79.3 percent. The adjusted probability of receiving newer versus traditional antibiotics for DTR infections was greater for patients with bacteremia and chronic diseases and was lower for those with do-not-resuscitate status, acute liver failure, and Acinetobacter baumannii complex and other nonpseudomonal nonfermenter pathogens.
"There is a stark imbalance between available new antibiotics and unmet pathogen targets," the authors write. "These findings call for paradigm-changing countermeasures."
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2024
Read this next
Early-Life Infection Burden Linked to Risk for Later Infections
THURSDAY, Jan. 9, 2025 -- Early-life infection burden is associated with an increased risk for later moderate-to-severe infections and systemic antibiotic treatments to age 10 or...
FDA: Listeria Concerns Prompt Broccoli Recall at Walmart Stores
FRIDAY, Jan. 3, 2025 -- Braga Fresh is voluntarily issuing a recall of its Marketside Broccoli Florets due to possible Listeria contamination, according to a company announcement...
2001-2010 to 2011-2022 Saw Rise in Incidence of Zoonotic Disease Tularemia
THURSDAY, Jan. 2, 2025 -- The incidence of tularemia, a rare nationally notifiable zoonosis caused by Francisella tularensis, increased from 2001-2010 to 2011-2022, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.